title: Pilot study of low-molecular-weight heparin in the treatment of acute ischemic stroke.
abstract: BACKGROUND
  Our purpose was to assess the feasibility and risk of performing a double-blind placebo-controlled study of low-molecular-weight heparin in the treatment of acute ischemic stroke.
  
  
  METHODS
  Fifty-five patients were treated within 48 hours of stroke onset. Pretreatment computed tomography was performed to rule out cerebral hemorrhage. Fraxiparine (6000 IU per day) was given subcutaneously for 7 days. No adverse reaction was encountered during the treatment period. At 3 months, 26 patients were independent, 21 moderately disabled, 4 severely disabled, and 4 dead.
  
  
  CONCLUSIONS
  It would be safe and practical to conduct a clinical trial on the use of Fraxiparine in the treatment of acute ischemic stroke.
authors.affiliation: Department of Medicine, Chinese University of Hong Kong, Shatin.
authors.forename: R
authors.initials: R
authors.lastname: Kay
authors.forename: K S
authors.initials: KS
authors.lastname: Wong
authors.forename: J
authors.initials: J
authors.lastname: Woo
mesh_terms: D000208:Acute Disease; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002545:Brain Ischemia / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D017762:Nadroparin / Q000627:therapeutic use*; D010865:Pilot Projects
chemical_list: D017762:Nadroparin